Posted by Michael Wonder on 03 Dec 2016
CADTH publishes final outcome for Afinitor (everolimus)
1 December 2016 - The outcome relates to the use of everolimus for the treatment of patients with a neuroendocrine tumour of gastro-intestinal or lung origin.
The pERC has recommended the reimbursement of everolimus for the treatment of adults with an unresectable, locally advanced or metastatic, well differentiated non-functional, progressive neuroendocrine tumour of gastro-intestinal or lung origin.
The recommendation comes with the usual caveat; the cost-effectiveness needs to be improved to an acceptable level.
